What is the dosage and frequency of Tropisetron (Hensetron) for nausea and vomiting management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tropisetron (Hensetron) Dosage and Frequency for Nausea and Vomiting Management

The standard dosage of Tropisetron (Hensetron) for nausea and vomiting management is 5 mg once daily, administered either orally or intravenously. 1

Standard Dosing Regimen

  • Tropisetron is administered as a 5 mg dose once daily for the management of nausea and vomiting 1
  • For intravenous administration, the drug should be given over 15 minutes, preferably before the start of chemotherapy or other emetogenic treatment 2
  • For oral administration, the 5 mg dose can be taken once daily 1
  • The recommended dosing schedule places Tropisetron among other serotonin (5-HT3) antagonists that are typically administered once daily 1

Clinical Applications

  • Tropisetron is primarily used for chemotherapy-induced nausea and vomiting (CINV), particularly for moderately to severely emetogenic chemotherapy regimens 3
  • For postoperative nausea and vomiting (PONV), lower doses may be effective, with 2 mg appearing to be the optimal dose 4
  • For acute nausea and vomiting (day 1 of chemotherapy), Tropisetron as a single agent provides complete control in 52-66% of patients 2, 5
  • For delayed nausea and vomiting (days 2-6), Tropisetron is less effective as monotherapy but still provides benefit 3

Combination Therapy

  • Adding dexamethasone to Tropisetron significantly improves antiemetic efficacy 6
  • The combination of dexamethasone and Tropisetron provides complete control of cisplatin-induced nausea and vomiting in 69-97% of patients compared to 46-80% with Tropisetron monotherapy 3
  • For patients with incomplete control on Tropisetron alone, adding dexamethasone (day 1: 0.2 mg/kg IV; days 2-6: 8 mg orally) significantly increases complete response rates 6
  • For refractory cases, adding a dopamine antagonist like metoclopramide may provide additional benefit 1, 7

Important Considerations

  • Increasing the dose beyond 5 mg does not improve efficacy; studies comparing 5 mg, 10 mg, 20 mg, and 40 mg showed no significant differences in control of acute symptoms 2
  • Tropisetron has similar efficacy to other 5-HT3 receptor antagonists (ondansetron, granisetron, palonosetron) for controlling acute nausea and vomiting 3
  • Tropisetron is effective in patients who have previously failed conventional antiemetic therapy, with 52% achieving control of acute vomiting compared to 25% with standard therapy 5
  • Common side effects include headache, constipation, and occasionally diarrhea, but extrapyramidal symptoms are rare 5

Special Scenarios

  • For multiple-day chemotherapy, Tropisetron should be administered daily on each day of chemotherapy 1
  • For refractory nausea and vomiting, adding dopamine antagonists to Tropisetron and corticosteroids is recommended 1
  • For high-dose chemotherapy, full doses of Tropisetron should be administered intravenously along with corticosteroids and dopamine antagonists 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Dose-finding study of tropisetron in cisplatin-induced nausea and vomiting.

Annals of oncology : official journal of the European Society for Medical Oncology, 1994

Research

Optimal combination therapy with tropisetron in 445 patients with incomplete control of chemotherapy-induced nausea and vomiting.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994

Guideline

Antiemetic Therapy for Nausea and Vomiting

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.